Table 6.

Trials’ subset and sensitivity analyses for prognostic analysis in control arm for OS, PFS and ORR

	Main analysis	Trials’ subset analysis		Sensitivity analyses
		Bevacizumab in control arm		Only phase III (without PEAK)	Only first line (without 20050181)
Parameter		Yes	No
OS
HR (95% CI)	1.38 (1.17–1.63)	1.41 (1.11–1.79)	1.36 (1.08–1.70)	1.32 (1.12–1.57)	1.36 (1.14–1.63)
P value	<0.001	0.005	0.008	0.001	<0.001
P value for interactiona		0.82
P value for heterogeneity	0.34	0.07	0.84	0.92	0.36
PFS
HR (95% CI)	1.25 (1.06–1.47)	1.18 (0.95–1.47)	1.33 (1.05–1.70)	1.25 (1.06–1.48)	1.23 (1.03–1.47)
P value	0.008	0.14	0.02	0.01	0.02
P value for interactiona		0.47
P value for heterogeneity	0.71	0.43	0.70	0.71	0.74
ORR
OR (95% CI)	0.56 (0.43–0.73)	0.56 (0.40–0.79)	0.56 (0.36–0.87)	0.55 (0.41–0.72)	0.57 (0.44–0.75)
P value	<0.001	<0.001	0.009	<0.001	<0.001
P value for interactiona		0.98
P value for heterogeneity	0.71	0.67	0.34	0.76	0.89

^aTest comparing the HRs between the two trial subsets (with/without bevacizumab).

CI, confidence interval; HR, hazard ratio; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.